The Botswana Network on Ethics, Law and HIV/AIDS (BONELA) has welcomed the Ministry of Health’s decision to roll out Lenacapavir, an injectable HIV prevention drug expected to strengthen the country’s response to new infections. The announcement comes at a time when Botswana continues to face challenges in reducing HIV transmission, particularly among young people. BONELA has described the move as a timely and important step that aligns with ongoing efforts to expand access to modern prevention tools. The organization believes that innovation in HIV prevention is critical to meeting national and global targets. The introduction of Lenacapavir adds another layer to Botswana’s existing prevention strategies and reflects a shift toward more advanced medical interventions.
BONELA Programmes Coordinator Katlego Sechele has emphasized that the new intervention could significantly reduce the number of new HIV infections in the country. He noted that injectable prevention options like Lenacapavir offer an alternative for individuals who may struggle with daily oral medication adherence. This is particularly relevant for younger populations who face barriers such as stigma, inconsistent access to healthcare services, and lifestyle factors that affect treatment consistency. Sechele explained that long-acting prevention methods can improve protection levels by reducing the risk of missed doses. He added that the effectiveness of such innovations depends on proper rollout, education, and community awareness.
Sechele also referenced findings from the Botswana AIDS Impact Survey, which show a concerning rise in new HIV infections among young people. These findings highlight a persistent gap in prevention efforts despite years of public health campaigns and treatment availability. The data suggests that young people remain one of the most vulnerable groups, requiring targeted and adaptable interventions. According to Sechele, this trend underscores the urgency of introducing innovative tools like Lenacapavir into the national prevention strategy. He stressed that without new approaches, Botswana risks slowing progress in its fight against HIV.
The introduction of Lenacapavir is expected to complement existing HIV prevention measures such as condoms, PrEP, and community outreach programs. Health experts view injectable prevention methods as a breakthrough because they reduce the need for daily adherence, which has been a major challenge in traditional prevention models. In addition, long-acting injectable options can help reduce stigma associated with taking daily HIV prevention pills. This can improve uptake among individuals who might otherwise avoid preventive medication due to social pressure or privacy concerns. The Ministry of Health’s decision reflects growing global momentum toward expanding biomedical HIV prevention tools.
BONELA has also highlighted the importance of ensuring equitable access during the rollout process. The organization has stressed that rural communities, young women, and high-risk groups must not be left behind in the distribution of Lenacapavir. Accessibility, affordability, and awareness will play a major role in determining the success of the program. Health education campaigns will be essential to ensure that communities understand how the drug works and who qualifies for it. BONELA believes that inclusive implementation will determine whether the intervention achieves its intended impact.
The broader HIV response in Botswana continues to evolve as the country adapts to changing patterns of infection and treatment needs. While significant progress has been made over the years in reducing AIDS-related deaths and expanding treatment access, new infections among young people remain a concern. The introduction of Lenacapavir represents a shift toward prevention strategies that are more aligned with modern healthcare challenges. Stakeholders argue that combining biomedical innovation with education and community engagement will produce stronger outcomes. This integrated approach is seen as essential for long-term success.
BONELA’s support for the rollout reflects growing recognition that innovation is necessary to sustain progress in HIV prevention. The organization has consistently advocated for rights-based and science-driven approaches to public health challenges. With Lenacapavir now set to become part of Botswana’s prevention toolkit, expectations are high for measurable improvements in infection rates, especially among youth. The success of the program will depend on effective implementation, public trust, and continuous monitoring. As Botswana moves forward, the focus remains on reducing new infections and ensuring that all populations have access to effective prevention options.
